Article
Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.
Journal of the National Cancer Institute - 1 Oct 2018
Depuydt Pauline, Boeva Valentina, Hocking Toby D, Cannoodt Robrecht, Ambros Inge M, Ambros Peter F, Asgharzadeh Shahab, Attiyeh Edward F, Combaret Valérie, Defferrari Raffaella, Fischer Matthias, Hero Barbara, Hogarty Michael D, Irwin Meredith S, Koster Jan, Kreissman Susan, Ladenstein Ruth, Lapouble Eve, Laureys Geneviève, London Wendy B, Mazzocco Katia, Nakagawara Akira, Noguera Rosa, Ohira Miki, Park Julie R, Pötschger Ulrike, Theissen Jessica, Tonini Gian Paolo, Valteau-Couanet Dominique, Varesio Luigi, Versteeg Rogier, Speleman Frank, Maris John M, Schleiermacher Gudrun, De Preter Katleen
Abstract excerpt
Background: Neuroblastoma is characterized by substantial clinical heterogeneity. Despite intensive treatment, the survival rates of high-risk neuroblastoma patients are still disappointingly low. Somatic chromosomal copy number aberrations have been shown to be associated with patient outcome, particularly in low- and intermediate-risk neuroblastoma patients. To improve outcome prediction in high-risk...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.